| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
R5-O-Methylvisamminol's primary targets are related to inflammatory and allergic responses. It has been shown to inhibit the release of histamine from mast cells, suggesting an anti-allergic mechanism. It also exhibits anti-inflammatory activity by modulating the production of pro-inflammatory cytokines and mediators.
|
|---|---|
| ln Vitro |
In vitro, R5-O-Methylvisamminol has been shown to inhibit histamine release from mast cells. It also exhibits anti-inflammatory activity by inhibiting the production of pro-inflammatory cytokines such as TNF-α and IL-6 in macrophages. Its activity is dose-dependent, with higher concentrations leading to greater inhibition.
|
| ln Vivo |
Specific in vivo activity data for R5-O-Methylvisamminol is not detailed in the provided search results. As a bioactive compound from S. divaricata, it is likely to contribute to the anti-inflammatory and analgesic effects of the plant extract in vivo. Animal models of inflammation and allergy would be used to assess its efficacy.
|
| Enzyme Assay |
The in vitro activity of R5-O-Methylvisamminol is assessed using various cell-based assays. The inhibition of histamine release is assessed in mast cells (e.g., RBL-2H3 cells or rat peritoneal mast cells). Cells are sensitized with IgE and then stimulated with an antigen (e.g., DNP-BSA) in the presence of various concentrations of R5-O-Methylvisamminol. The amount of histamine released into the culture medium is measured by ELISA or by a fluorometric assay. The anti-inflammatory activity is assessed in macrophages (e.g., RAW 264.7 cells) stimulated with LPS. Cells are treated with various concentrations of R5-O-Methylvisamminol, and the production of TNF-α and IL-6 is measured by ELISA.
|
| Cell Assay |
For cellular assays, mast cells (e.g., RBL-2H3 cells) or macrophages (e.g., RAW 264.7 cells) are cultured in appropriate media (e.g., DMEM with 10% fetal bovine serum). Cells are treated with various concentrations of R5-O-Methylvisamminol (typically ranging from 1 to 100 µM) for different time periods (e.g., 1-24 hours). Histamine release is measured in the culture supernatant. The expression of inflammatory mediators (e.g., COX-2, iNOS) is analyzed by quantitative real-time PCR or Western blotting.
|
| Animal Protocol |
In vivo studies with R5-O-Methylvisamminol are not well-documented in the provided search results. If conducted, they would likely involve administration of the compound to animal models of inflammation or allergy. For example, in a mouse model of ear edema, the compound would be applied topically or administered orally, and the reduction in ear swelling would be measured.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for R5-O-Methylvisamminol is not available in the provided search results. As a small molecule with a molecular weight of 290.31 g/mol, it is expected to have reasonable oral bioavailability. Its absorption, distribution, metabolism, and excretion would require further investigation.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for R5-O-Methylvisamminol is not available in the provided search results. As a natural compound from a plant used in traditional medicine, it is generally considered to have a low toxicity profile. However, comprehensive toxicological studies are required to establish its full safety profile.
|
| References | |
| Additional Infomation |
5-O-methylvexamine alcohol is an oxygen heterocyclic compound and an organic heterotricyclic compound. It has been reported to exist in Angelica sinensis, Tribulus terrestris, and Saposhnikovia divaricata, and relevant data are available for reference.
R5-O-Methylvisamminol is a bioactive compound from Saposhnikovia divaricata, a plant used in traditional Chinese medicine for the treatment of inflammatory and allergic conditions. It is a research compound used to study the pharmacological effects of S. divaricata and its active components. It is not approved for clinical use. |
| Molecular Formula |
C16H18O5
|
|---|---|
| Molecular Weight |
290.31112
|
| Exact Mass |
290.115
|
| CAS # |
80681-42-1
|
| PubChem CID |
441970
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.281 g/cm3
|
| Boiling Point |
480.6ºC at 760 mmHg
|
| Melting Point |
133-135 °C
|
| Flash Point |
179.1ºC
|
| Index of Refraction |
1.58
|
| LogP |
2.184
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
21
|
| Complexity |
469
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1=CC(=O)C2=C(C3=C(C=C2O1)O[C@@H](C3)C(C)(C)O)OC
|
| InChi Key |
DGFLRNOCLJGHLY-ZDUSSCGKSA-N
|
| InChi Code |
InChI=1S/C16H18O5/c1-8-5-10(17)14-12(20-8)7-11-9(15(14)19-4)6-13(21-11)16(2,3)18/h5,7,13,18H,6H2,1-4H3/t13-/m0/s1
|
| Chemical Name |
(2S)-2-(2-hydroxypropan-2-yl)-4-methoxy-7-methyl-2,3-dihydrofuro[3,2-g]chromen-5-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~172.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4446 mL | 17.2230 mL | 34.4459 mL | |
| 5 mM | 0.6889 mL | 3.4446 mL | 6.8892 mL | |
| 10 mM | 0.3445 mL | 1.7223 mL | 3.4446 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
